Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Follow-Up Questions
Catalyst Pharmaceuticals Inc (CPRX)'in P/E oranı nedir?
Catalyst Pharmaceuticals Inc 'in P/E oranı 15.3466 'dir
Catalyst Pharmaceuticals Inc 'in CEO'su kimdir?
Mr. Richard Daly 2015 'den beri şirketle birlikte olan Catalyst Pharmaceuticals Inc 'in President 'ıdır.
CPRX hissesinin fiyat performansı nasıl?
CPRX 'in mevcut fiyatı $20.93 'dir, son işlem günde 1.87% increased etti.
Catalyst Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Catalyst Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 10 analist Catalyst Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 7 güçlü al, 6 al, 1 tut, 0 sat ve 7 güçlü sat içermektedir